• Latest Posts

Biotech of the Week: ThromboGenics & Therapies against Eye Disease

Two of the Biggest European Biotechs launch Antibody Program together

Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

Exploiting the Power of NGS to Diagnose Rare Diseases

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

ADVERTISEMENT

This Bone Cell Therapy Could Make it to a Shelf Near You

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

World’s Best Journal in Medicine Publishes on Phase II Llama Antibodies

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

From Belgium: 3D-Bioprinted ‘Waffle’ to Fix Broken Bones

Gilead On Board, But Still No Easy Sailing for Galapagos with Phase IIa Failure

ADVERTISEMENT